Breast Cancer Treatment Guidelines

The faculty in the Breast Oncology Program at Dana-Farber Brigham Cancer Center have developed guidelines on how to best utilize certain treatments recently approved by the Food and Drug Administration (FDA). The guidelines were drafted using data from available clinical trials and presented for feedback and expert consensus to a diverse group of Dana-Farber Brigham physicians, nurses, clinical investigators, lab investigators, translational researchers, administrators, and patient advocates. We are pleased to share our recommended guidelines which may be a helpful reference when using these new agents. In our discussions, we considered:

The reports include reviews of the clinical trials that led to FDA approval as well as the above-mentioned recommendations for patient selection and treatment.

 


Treatment Guidelines: Use of Bone-Modifying Agents in Patients with Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings in October 2022 and February 2023 to discuss recommendations for bone-modifying agents in patients with breast cancer.

Treatment Guidelines: Tailored Echocardiographic Monitoring in Breast Cancer Patients Receiving HER2-Directed Treatments and/or Anthracyclines

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings in 2022 and 2023 to discuss recommendations for tailored echocardiographic monitoring in patients receiving HER2-directed treatments and/or anthracyclines.

Treatment Guidelines: Sacituzumab Govitecan for Metastatic, HR-Positive, HER2-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on April 5, 2023 to discuss recommendations for the for the use of sacituzumab govitecan in patients with metastatic, HR-positive, HER2-negative breast cancer.

Treatment Guidelines: Elacestrant for Advanced Estrogen Receptor-Positive Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on February 24 and May 5, 2023 to discuss recommendations for the use of elacestrant in patients with advanced estrogen receptor-positive breast cancer.

Treatment Guidelines: Trastuzumab Deruxtecan (T-DXd) for Metastatic, HER2-low Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on July 1 and July 8, 2022 to discuss recommendations for the use of trastuzumab deruxtecan (T-DXd) in patients with metastatic, HER2-low breast cancer.

Treatment Guidelines: Pembrolizumab for Early-Stage Triple-Negative Breast Cancer

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on August 4, September 3, October 8, 2021, and June 24, 2022 to discuss recommendations for the use of pembrolizumab in patients with early-stage TNBC.

Treatment Guidelines: Reflex Testing of OncotypeDX for Early Stage Breast Cancer

The Breast Oncology Center held multidisciplinary meetings to discuss recommendations for updated criteria for reflex testing of OncotypeDX in patients with resected, hormone receptor positive, HER-2 negative, early breast cancer.

Treatment Guidelines: Adjuvant Olaparib for BRCA1/2 Variant Carriers

The Breast Oncology Center at Dana-Farber Brigham Cancer Center held multidisciplinary meetings on May 6, May 20, June 1, and August 5, 2022 to discuss recommendations for the use of adjuvant olaparib for high-risk, breast cancer in BRCA1/2 carriers.

Additional guidelines will be published here as new agents are approved by the FDA.